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1038Background: The present study examined a cardiac passive restraint device which applies epicardial pressure
(HeartNet Implant; Paracor Medical, Inc, Sunnyvale, Calif) in a clinically relevant model of dilated cardiomy-
opathy to determine effects on hemodynamic and myocardial blood flow patterns.
Methods: Dilated cardiomyopatht was established in 10 pigs (3 weeks of atrial pacing, 240 beats/min). Hemo-
dynamic parameters and regional left ventricular blood flow were measured under baseline conditions and after
acute placement of the HeartNet Implant. Measurements were repeated after adenosine infusion, allowing max-
imal coronary vasodilation and coronary flow reserve to be determined.
Results: Left ventricular dilation and systolic dysfunction occurred relative to baseline as measured by echocar-
diography. Left ventricular end-diastolic dimension increased and left ventricular fractional shortening de-
creased (3.8  0.1 vs 6.1  0.2 cm and 31.6%  0.5% vs 16.2%  2.1%, both P< .05, respectively),
consistent with the dilated cardiomyopathy phenotype. The HeartNet Implant was successfully deployed with-
out arrhythmias and a computed median mid–left ventricular epicardial pressure of 1.4 mm Hg was applied by
the HeartNet Implant throughout the cardiac cycle. Acute HeartNet placement did not adversely affect steady
state hemodynamics. With the HeartNet Implant in place, coronary reserve was significantly blunted.
Conclusions: In a large animal model of dilated cardiomyopathy, the cardiac passive restraint device did not
appear to adversely affect basal resting myocardial blood flow. However, after acute HeartNet Implant place-
ment, left ventricular maximal coronary reserve was blunted. These unique results suggest that cardiac passive
restraint devices that apply epicardial transmural pressure can alter myocardial blood flow patterns in a model of
dilated cardiomyopathy. Whether this blunting of coronary reserve holds clinical relevance with chronic passive
restraint device placement remains unestablished. (J Thorac Cardiovasc Surg 2011;142:1038-45)In the past decade the number of patients discharged from the
hospitalwith a diagnosis of congestive heart failure (CHF) has
doubled andCHF is now themost common reason for hospital
admission in the elderly patient population. As the population
ages, the incidence of CHF will increase and continue to be
a major health care issue. The progression of CHF is charac-
terized by left ventricular (LV) dilation and subsequent pump
dysfunction. Current pharmacologic therapies for CHF in-
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The Journal of Thoracic and Cardiovascular Surcome activated during progression of the disease. These
pharmacologic treatment strategiesmayprovide symptomatic
relief, but the LV remodeling process can continue unabated.
Surgical treatment for LV dilation and systolic dysfunction
has also been pursued, including the use of cardiac support de-
vices that are postulated to attenuate progressive dilation and
stabilize systolic function.1-7 For example, placement of
passive cardiac support devices in patients with dilated
cardiomyopathy (DCM), a classic phenotypic presentation
of LV dilation and CHF, has been performed with an aim of
altering the course of CHF.1-3,5,6 However, a number of
issues surrounding the deployment of these devices in the
context of DCM remain. Specifically, the acute
hemodynamic consequences, and more important the direct
effect on myocardial blood flow patterns with acute
placement of a cardiac support device, remain poorly
understood. A particular passive support device that has
advanced to clinical trials is the HeartNet Implant (model
P140; Paracor Medical, Inc, Sunnyvale, Calif), which
consists of silicone-insulated nitinolwire forms.TheHeartNet
Implant provides resistance to circumferential dilation via
transmural myocardial pressure.5-7 In the context of DCM,gery c November 2011
Abbreviations and Acronyms
CHF ¼ congestive heart failure
DCM ¼ dilated cardiomyopathy
ECG ¼ electrocardiogram (graphy)
LV ¼ left ventricle (ventricular)
RV ¼ right ventricle (ventricular)
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Da shift in the volume/wall thickness ratio occurs, whereby
changes in epicardial pressure may directly affect intrinsic
myocardial resistance to blood flow. These changes in
pressure may be of particular relevance considering the
HeartNet Implant may exert additive transmural
compressive forces during diastole, the peak of myocardial
blood flow delivery. However, whether this theoretical
concern can be demonstrated under physiologic conditions
relevant to DCM remains unknown. Accordingly, the
present study used a large animal model that recapitulates
the phenotype of DCM8 to measure hemodynamics andmyo-
cardial blood flow patterns at rest and after maximal coronary
arterydilatation in the contextofHeartNet Implant placement.
METHODS
The study used a DCM model that has been previously characterized by
this laboratory.8-15 After the development of DCM, a terminal study was
performed at which time baseline systemic hemodynamics and myocardial
blood flow were measured with and without the HeartNet Implant in place.
Two models of the HeartNet system were used: the model P140 system,
which is currently undergoing study in the PEERLESS-HF pivotal trial in
the United States and Canada, and the model P150 system, which is
a next-generation HeartNet system. All animals were treated and cared for
in accordance with the National Institutes of Health’s ‘‘Guide for the Care
and Use of Laboratory Animals’’ (National Institutes of Health, 1996).
DCM Induction and Echocardiography
Yorkshire pigs (n¼ 10; 25 kg castratedmales) underwent pacemaker im-
plantation for the purposes of establishing pacing-induced DCM. In brief,
a sterile left thoracotomy and a small pericardiotomy were performed, ex-
posing the left atrium. A shielded pacemaker lead (CapSure 4965; Med-
tronic, Inc, Minneapolis, Minn) was sutured onto the left atrium and
connected to a pacemaker (Telectronics model 1256; St Jude Medical,
Inc, Sylmar, Calif),whichwas buried in a subcutaneous pocket. The pericar-
dium was irrigated and approximated, the thoracotomy closed, and the
pleural space evacuated of air. On postoperative day 5, baseline echocardi-
ographywasperformed (Agilent Sonos 5500, 3.5MHzprobe;AgilentTech-
nologies, Inc, Santa Clara, Calif) and the pacemaker was then activated
(240 beats/min). A 1:1 rate of capture was verified via electrocardiographic
(ECG) recordings and echocardiography. Cardiac auscultation and ECG
recordings were performed frequently during the pacing protocol to ensure
continuous capture. At 18 to 21 days of pacing, the animal was returned to
the laboratory for pacemaker deactivation, and a second echocardiogram
was performed.
Hemodynamic and Myocardial Blood Flow
Measurements
For the terminal studies, all animals were instrumented in identical fash-
ion. Anesthetic induction commenced using isoflurane (3%) and nitrousThe Journal of Thoracic and Caroxide (33%) delivered via face mask. A 2-mg/kg dose of sufentanyl
(Elkins-Sinn, Inc, Cherry Hill, NJ), a 0.1-mg/kg dose of etomidate (Ami-
date; Elkins-Sinn, Inc), and a 10-mg dose of vecuronium (Bedford Labora-
tories, Bedford, Ohio) were then administered intravenously, and an
endotracheal tubewas placed. Anesthesia was maintained with the delivery
of inhaled isoflurane (0.5%) and intravenous morphine (Elkins-Sinn, Inc)
at 3 mg $ kg1 $ h1. A bolus of amiodarone (5 mg/kg) (APP Pharmaceuti-
cals LLC, Schaumburg, Ill) was administered, an intravenous infusion of
lidocaine (Hospira, Inc, Lake Forest, Ill) was initiated at 4 mg $ kg1 $
h1, and magnesium chloride (1 g) (Luitpold Pharmaceuticals, Inc, Shirley,
NY) was delivered. After stabilization of the surgical anesthetic plane, an
intravenous infusion of vecuronium was initiated at 15 mg $ kg1 $ h1.
A multilumened thermodilution catheter (7.5F; Baxter Healthcare, Inc,
Irvine, Calif) was positioned in the pulmonary artery via the left external
jugular vein. An 8F introducer with a sidearm was placed in the right ca-
rotid artery for blood pressure measurements and subsequent placement
of the LV pressure/infusion catheter. A previously calibrated microtipped
transducer catheter with a side port for infusion and a pigtail catheter
(7.5F; Millar Instruments, Inc, Houston, Tex) were advanced through the
hemostatic sheath and positioned in the LV. The left carotid artery was can-
nulated with an 8F hemostatic introducer with a sidearm for arterial blood
pressure measurements and withdrawal of reference blood samples. A ster-
notomy was performed and the pericardium was opened and supported by
pericardial sutures before baseline measurements. After instrumentation
and a 30-minute stabilization period, the experimental protocol was begun.
Experimental Protocol
Steady state hemodynamics, specifically heart rate, oxygen saturation, ar-
terial blood pressure, pulmonary artery pressure, pulmonary capillarywedge
pressure, LV pressure, and cardiac output, as well as myocardial blood flow,
were recorded with the ventilator temporarily suspended to prevent respira-
tory artifact. LV peak positive dP/dt was determined from the digitized LV
pressure signal. After completion of the steady state hemodynamic measure-
ments, a set of fluorescentmicrosphereswas injected for the determination of
myocardial blood flow.14-17 In brief, blue–green (excitation 430, emission
460), yellow (excitation 490, emission 520), red–orange (excitation 530,
emission 570), or scarlet (excitation 645, emission 680) fluorescent
microspheres (3 3 106; Molecular Probes, Eugene, Ore) were injected
into the LV via the pigtail catheter. A reference aortic blood sample was
withdrawn from the contralateral carotid artery at a rate of 7 mL/min,
which was initiated 5 seconds before injection and continued for 120
seconds after injection. Next, adenosine (1.5 mmoL $ kg1 $ h1) was
infused through the venous access port, and after 15 minutes of infusion,
hemodynamics and LV pressures were recorded and fluorescent
microspheres delivered. The adenosine infusion allowed for maximal
coronary vasodilation and determination of maximal coronary blood flow
reserve.8,10 After microsphere delivery, the adenosine infusion was
terminated, resulting in a rapid normalization of hemodynamics.
HeartNet Implant Placement and Measurements
After steady state baseline measurements, the HeartNet Implant was
placed circumferentially around the LVand right ventricle (RV). Two ver-
sions of the HeartNet Implant were modified for porcine sizing and used for
the studies described herein: the P140 HeartNet and the P150 HeartNet Im-
plant. Both the P140 and P150 HeartNet Implants consist of a series of cir-
cumferentially oriented silicone-jacketed nitinol wire-form rings that
provide elastic support to the ventricular wall (approximately 0.5–2.5
mm Hg throughout the cardiac cycle). The modified implants consisted
of 3 rows and were designed to fit a heart with a maximum circumference
measuring approximately 40 cm in circumference. The animals received
either P140 Implants (n ¼ 5) or P150 Implants (n ¼ 5) as determined by
a preassigned randomization table. A demonstration of the intraoperative
P140 Implant placement, assuring proper circumferential deployment, is
shown in Figure 1, A. Furthermore, after visual confirmation of appropriatediovascular Surgery c Volume 142, Number 5 1039
FIGURE 1. A, Intraoperative placement of the P140 Implant onto a DCM
pig heart. B, Fluoroscopic image of the P140 Implant confirming circum-
ferential deployment in the posterior region of the DCM heart. DCM,
Dilated cardiomyopathy.
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Ddeployment, adequate posterior region placement was confirmed using
fluoroscopic imaging (Phillips BV 300; Phillips Medical Systems, Bothell,
Wash). A representative fluoroscopic image of the LV with the P140 Im-
plant in place is shown in Figure 1, B. The diameters of the cardiac silhou-
ette at the top circumferential ring of the HeartNet device changed from
a baseline measurement of 244 4 pixels to 240 4 pixels (ratio of silhou-
ette diameter after HeartNet placement to baseline diameter: 0.99  0.01;
P ¼ .82). Once the HeartNet Implant had been placed, a second 30-minute
stabilization period was observed, and then steady state hemodynamic
measurements, LV pressure measurements, and fluorescent microsphere
delivery were performed as described in the preceding section. After these
measurements, an adenosine infusion was again instituted and the hemody-
namic and coronary flow measurements were repeated.
Tissue Harvest
Isoflurane anesthesia was increased to 5% and, with a full surgical plane
of anesthesia, the heart was harvested. The LVand RV were dissected free,
weighed, and subsequently fixed in 10% formaldehyde to facilitate slicing.
The myocardium was later dissected into 2 RV regions and 18 LV regions,
including epicardial and endocardial regions. Samples of approximately 3 g
eachwere collected from each region and digested in a potassiumhydroxide
solution as previously described.8-10,13,16,17 The aortic blood samples were
extracted with an identical digest solution. The fluorescence of each
extracted sample was subjected to spectrofluorimetry.
Computations and Data Analysis
Echocardiographic indices of LV end-diastolic dimension and frac-
tional shortening were determined and compared between baseline pre-
pacing values and DCM values using a t test. From the hemodynamic
data, pulmonary and systemic vascular resistances were computed from
the thermodilution cardiac output and pressure measurements using stan-
dard formulas. The pulmonary artery waveforms recorded during determi-
nation of pulmonary capillary wedge pressure were analyzed to determine
the amplitude of the a-wave (between the P-wave and the QRS complex
on the ECG) and v-wave (coincident with the termination of the T-wave
on the ECG) tracing before and after placement of the HeartNet devices.
Regional blood flow computations were determined by the standard for-
mula: Qm ¼ (Ar 3 Am)/Qr, where Qm is the blood flow in milliliters
per minute, Ar is the fluorescence of the aortic reference sample, Am is
the fluorescence of the tissue sample, and Qr is the withdrawal rate of
the reference sample.20 Final blood flow values were normalized to tissue
sample weights and expressed as milliliters per minute per gram. Compar-
isons of hemodynamics and myocardial blood flow response to adenosine,1040 The Journal of Thoracic and Cardiovascular Surboth with and without the HeartNet Implant placed, were made by re-
peated measures mixed model analysis of variance on each outcome
variable, with grouping (baseline or HeartNet Implant) as the between-
subjects variable and drug status (steady state vs adenosine) as the
within-subjects variable. Finally, the relative change from absolute base-
line steady state values to values after HeartNet Implant placement and
adenosine infusion were calculated and log transformed, inasmuch as
they did not conform to a normal distribution. All pairwise comparisons
were performed by Tukey adjusted P values. In addition, potential Heart-
Net Implant/adenosine interactions were examined by analysis of vari-
ance. All statistical analyses were performed using the SAS statistical
software (version 9.2; SAS Institute, Inc, Cary, NC) and statistical signif-
icance was considered at a ¼ .05 level. All data are presented as mean 
standard error of the mean. All authors had access to the data and its in-
terpretation and take full responsibility for its integrity. The funding
agency did not influence the interpretation of the data.RESULTS
Echocardiographic measures confirmed that the DCM
phenotype was established by rapid atrial pacing and pro-
duced increased LV end-diastolic dimension (3.8  0.1
cm vs 6.1 0.2 cm), decreased LVend-diastolic wall thick-
ness (0.8 0.1cm vs 0.6 0.1 cm), and decreased LV frac-
tional shortening (31.6%  0.5% vs 16.2%  2.1%), as
compared with baseline values, consistent with prior reports
from this laboratory and others.8-14,18-20 The amplitudes of
the a- and v-waves on the pulmonary capillary wedge
pressure traces were 18  3 mm Hg and 22  3 mm Hg,
respectively, suggesting the presence of at least mild and/
or moderate mitral regurgitation, consistent with the
development of tachycardia-induced DCM.18-20 The
hemodynamic effects observed with adenosine infusion
while the HeartNet Implant was placed on the heart are
reported in Table 1. Hemodynamics were equivalent at
steady state and with adenosine in the pigs randomized to
P140 or P150 HeartNet Implant and, therefore, were com-
bined for all analyses for the purposes of statistical robust-
ness. A decrease in systemic blood pressure was observed
with adenosine administration, consistent with the systemic
vasodilatory effects of adenosine. After acute placement of
either the P140 or the P150 HeartNet Implant, steady state
hemodynamics were unchanged from baseline steady state
measurements. After HeartNet Implant placement, the am-
plitudes of the a- and v-waves on the pulmonary capillary
wedge pressure tracing were similar to baseline values
(a-wave: 18  3, P ¼ .77; v-wave: 21  3 mm Hg,
P ¼ .61, respectively), suggesting that there was minimal
to no acute effect of HeartNet Implant placement on the de-
gree of mitral regurgitation. Systemic blood pressure was
reduced with adenosine infusion. Myocardial blood flow
measurements at steady state and after adenosine, both
with and without HeartNet Implant placement, are reported
as LV endocardial, epicardial, or RV regional values
(Table 2). Consistent with prior reports, myocardial blood
flow was augmented by adenosine infusion in both cham-
bers and in all regions analyzed.8-10 After acute HeartNetgery c November 2011
TABLE 1. Hemodynamics in DCM pigs under steady state and after adenosine at baseline and with placement of model P140 or P150 HeartNet
Implants
Baseline HeartNet Implant
Steady state Adenosine Steady state Adenosine
Heart rate (beats/min) 101  7 94  6 108  7 105  8
LV pressures
LV peak (mm Hg) 107  7 95  5 118  8 103  8
LVEDP (mm Hg) 20  2 21  3 22  2 22  3
Peak positive dP/dt (mm Hg/s) 1229  113 1163  105 1461  137 1332  108
Peak negative dP/dt (mm Hg/s) 1626  120 1388  122 1540  102 1444  124
Systemic pressures
Systolic (mm Hg) 109  6 96  5 120  8 103  8
Diastolic (mm Hg) 69  5 51  5* 80  7 59  9*
Mean (mm Hg) 86  6 68  5* 98  8 76  9*
SVR (dyn $ s $ cm5) 2542  273 1714  267* 2767  223 1887  373*
Pulmonary pressures
Systolic (mm Hg) 32  3 30  3 35  2 34  3
Diastolic (mm Hg) 24  3 22  3 27  3 26  3
Mean (mm Hg) 28  3 26  3 31  3 30  3
PCWP (mm Hg) 19  3 19  3 21  3 23  3
PVR (dyn $ s $ cm5) 361  76 252  44 386  68 310  119
Cardiac output (L/min) 2.5  0.4 2.8  0.4 2.3  0.3 2.7  0.4
Values are presented as mean  standard error of the mean. DCM, Dilated cardiomyopathy; LV, left ventricular; LVEDP, left ventricular end diastolic pressure; dP/dt, rate of
pressure rise; SVR, systemic vascular resistance; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance. Sample size: n ¼ 10. *P< .05 versus
respective steady state.
TABLE 2. Myocardial blood flow in DCM pigs under steady state and after adenosine at baseline and with placement of model P140 or P150
HeartNet Implant
Baseline HeartNet Implant
Tissue region Steady state Adenosine Steady state Adenosine
LV base
Free wall
Endocardium 1.84  0.25 4.14  0.73* 2.73  0.39 3.15  0.38
Epicardium 1.89  0.21 3.79  0.51* 3.02  0.43* 2.92  0.34
Septal wall
Endocardium 1.97  0.32 3.71  0.56* 2.57  0.32 3.09  0.52
Epicardium 1.94  0.39 3.97  0.67* 2.64  0.41 3.34  0.68
LV mid
Free wall
Endocardium 2.12  0.26 4.54  0.78* 3.06  0.43 3.64  0.53
Epicardium 2.14  0.27 4.07  0.60* 3.19  0.42 2.99  0.36
Septal wall
Endocardium 2.13  0.30 3.84  0.68* 2.89  0.43 3.27  0.64
Epicardium 2.18  0.35 4.15  0.81* 3.01  0.50 3.56  0.65
LV apex
Free wall
Endocardium 2.08  0.26 4.00  0.64* 2.93  0.38 3.27  0.41
Epicardium 2.03  0.28 3.79  0.64* 2.86  0.42 2.82  0.47
Septal wall
Endocardium 2.20  0.31 4.12  0.84* 2.99  0.49 3.49  0.68
Epicardium 1.95  0.24 3.80  0.67* 2.85  0.45 3.33  0.65
RV
Free wall 1.62  0.24 3.80  0.65* 2.58  0.44 3.55  0.89*
Outflow tract 2.00  0.29 3.89  0.68* 2.93  0.44 3.61  0.72*
Values are presented as mean  standard error of the mean. Blood flow is reported as milliliters per minute per gram of tissue. DCM, Dilated cardiomyopathy; LV, left ventricle;
RV, right ventricle. Sample size: n ¼ 10 DCM pigs. *P<.05 vs baseline steady state.
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FIGURE 2. A, Average of left ventricular (LV) blood flow from all mea-
sured regions in DCM pigs (n ¼ 10). A significant increase in LV blood
flow values was observed under steady state conditions with adenosine ad-
ministration. The effect of adenosine on LV blood flow is attenuated after
acute HeartNet Implant placement. B, Average of right ventricular (RV)
blood flow from all measured regions in DCM pigs (n ¼ 10). Before and
after acute HeartNet Implant placement, blood flow values increased
from baseline steady state values with adenosine infusion.þP<.05 versus
baseline steady state. SS, Steady state; Ad, adenosine;DCM, dilated cardio-
myopathy.
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FIGURE 3. A, Average left ventricular (LV) blood flow demonstrated by
region at baseline under steady state conditions and after adenosine admin-
istration. Each region is the average blood flow from 10 DCM pigs. All LV
free wall regions show a consistent increase in myocardial blood flow with
adenosine administration. B, The same LV free wall regions, each the av-
erage of 10 DCM pigs, at steady state and with adenosine administration
after HeartNet Implant placement. The 3 LVepicardial regions show a de-
crease in blood flow as compared with the LV endocardial regions after
HeartNet Implant placement (P ¼ .02). DCM. Dilated cardiomyopathy.
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DImplant placement, steady state myocardial blood flow
increased from baseline steady state values and reached
statistical significance in the LV base–free wall epicardial
region. Moreover, after adenosine infusion, myocardial
blood flow did not reach similar values as compared
with the baseline adenosine state. Average LV and RV
myocardial blood flow changes with and without
HeartNet Implant are shown in Figure 2. Before HeartNet
Implant placement, maximal coronary blood flow response,
as assessed by adenosine infusion, increased from baseline1042 The Journal of Thoracic and Cardiovascular Sursteady state values. After acute HeartNet Implant place-
ment, steady state LVmyocardial blood flow values qualita-
tively increased but did not reach statistical significance.
With HeartNet placement and adenosine infusion, LV myo-
cardial blood flow did not significantly increase from either
baseline steady state or HeartNet steady state. The average
RV blood flow values, as shown in Figure 2, showed a sim-
ilar pattern, but with a notable exception. Specifically, aver-
age RV myocardial blood flow increased from baseline
steady state with adenosine infusion both before and after
HeartNet Implant placement.gery c November 2011
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FIGURE 4. A, Change in average left ventricular (LV) myocardial blood
flow from normalized baseline steady state values. The LV myocardial
blood flow values were increased under baseline adenosine and HeartNet
Implant steady state conditions, yet failed to reach statistical significance
under HeartNet Implant and adenosine condition. B, Change in average
right ventricular (RV) myocardial blood flow from normalized baseline
steady state values. RV myocardial blood flow values were elevated under
baseline adenosine, HeartNet Implant steady state, and HeartNet Implant
adenosine conditions. Sample size: n ¼ 10 dilated cardiomyopathy
(DCM) pigs.þP<.05 versus normalized baseline steady state value.
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DThrough amixedmodel analysis of variance, a significant
interaction between the HeartNet Implant and adenosine in-
fusion effects on LV myocardial blood flow was observed
(F ¼ 6.21, P ¼ .019). That is, the preparation with the
HeartNet Implant placed showed a significant influence
on adenosine-mediatedmyocardial blood flow, as compared
with baseline. A regional response analysis was performed
to determine whether the effect of acute HeartNet Implant
placement on adenosine-mediated LV blood flow was
global or regional (Figure 3). Before HeartNet Implant
placement, all LV free wall regions demonstrated a consis-
tent increase in blood flow with adenosine infusion. How-
ever, after acute HeartNet Implant placement, a selective
negative myocardial blood flow response was observed inThe Journal of Thoracic and Carthe LV free wall epicardial regions as compared with the re-
spective endocardial regions. The LV free wall epicardial
regions were more affected than the endocardial regions,
with respect to HeartNet Implant placement and adenosine
infusion (P ¼ .02).
The absolute change in LVand RVmyocardial blood flow
values as a function of steady state baseline values was com-
puted, as shown in Figure 4. LV myocardial blood flow
values after adenosine infusion and at steady state after
HeartNet Implant placement were increased from steady
state baseline. The LV myocardial blood flow after acute
HeartNet Implant placement and adenosine infusion ap-
peared elevated from baseline steady state but did not reach
statistical significance. RV myocardial blood flow was ele-
vated at all subsequent time points from normalized steady
state baseline values.
DISCUSSION
The fundamental structural phenotype of DCM involves
substantial LV chamber dilation and wall thinning, with an
alteration in the volume/wall thickness ratio. Because the di-
lated ventricle is the cornerstone of DCM, attempts have
been made to alter this inexorable disease course through
physical support and restraint of the heart. 1-7,21-23
However, whether and to what degree myocardial blood
flow patterns are acutely altered by HeartNet Implant
placement in the context of DCM remains unknown.
Accordingly, in the present study we evaluated 2 versions
of the HeartNet Implant in a clinically relevant model of
DCM to examine the effects of acute HeartNet Implant
placement on hemodynamics and myocardial blood flow
patterns. The pertinent findings of the study were 2-fold.
First, placement of the HeartNet Implant did not acutely
compromise hemodynamics in this well-established DCM
model. Second, LVmyocardial blood flow patterns were un-
changed at steady state after HeartNet Implant placement.
However, maximal coronary reserve was blunted, in abso-
lute and relative terms, from steady state baseline after
HeartNet Implant placement. Therefore, acute placement
of the HeartNet Implant in the porcine DCM model had
no negative steady state effects on hemodynamics or myo-
cardial blood flow. However, it remains to be established
whether and to what extent the acute effects on coronary re-
serve are operative after longer durations of deployment.
Several cardiac support devices have been developedwith
the goal of attenuating the progression of DCM.1-7,21-23 The
CorCap Cardiac Support Device (Acorn Cardiovascular,
Inc, St Paul, Minn) has been examined in several
experimental models of heart failure and has advanced
to clinical trials, demonstrating sustained reduction in LV
end-diastolic and end-systolic volumes compared with
controls.1 Whereas the CorCap device consists of a polyes-
ter-weave device that is placed around both ventricles, other
devices have used a splint approach to cardiac support.diovascular Surgery c Volume 142, Number 5 1043
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DSpecifically, the Myosplint system (Myocor, Maple Grove,
Minn) uses an implantable transventricular tension member
fixed between epicardial pads to disperse epicardial ten-
sion.21 The Myosplint device has fallen out of clinical
use owing to a lack of therapeutic effect and complications
of mitral valve insufficiency.22 The Paracor HeartNet
Implant has been examined in several animal models of
LV failure and dysfunction.6,23 For example, Magovern
and associates23 reported that long-termHeartNet implanta-
tion decreased postinfarction LV dilation in sheep. However,
no preclinical studies examining myocardial blood flow in
a DCM model have been undertaken, making the study
described herein unique.
The present study used a well-characterized rapid pacing
model that results in LV dilation and the hemodynamic phe-
notype of DCM.8-14 Acute HeartNet Implant placement in
this DCM model did not create hemodynamic compromise.
Taken together with the finding that the pulmonary
capillary wedge pressure waveforms after placement of the
HeartNet devices were similar to those recorded before
device deployment, it is unlikely that acute placement of
the device altered the degree of mitral regurgitation and/or
had confounding influence on the LV myocardial blood
flow measurements. Therefore, the myocardial blood flow
measurements were performed under an equivalent hemo-
dynamic state. After acute HeartNet Implant placement, LV
myocardial blood flow was not compromised. In fact, there
was a tendency for increased myocardial blood flow with
acute HeartNet Implant placement. The reasons for this
increase are likely multifactorial, including the surgical
manipulation required to deploy the implant, disruptive
electrical–mechanical events, neurohormonal stimulation,
and localized sympathetic stimulation from the implant and
the deployment procedure. Also, heart rate, a fundamental
determinant of myocardial oxygen demand and myocardial
blood flow, trended upward with HeartNet Implant
placement. Whether these changes in myocardial blood
flow and heart rate are maintained with long-term deploy-
ment of the HeartNet devices in the context of DCM remain
to be established.
Maximal coronary flow reserve can be defined as the in-
crease in coronary blood flow above basal flow values
when the coronary vasculature is maximally dilated.24 Al-
though there are many ways to assess myocardial flow re-
serve, one common method is through the intravenous
infusion of adenosine.24,25 In the present study, adenosine
infusion robustly augmented myocardial blood flow from
baseline steady state values, consistent with coronary
vasodilatory effects. However, maximal LV coronary blood
flow reserve, as defined by adenosine infusion compared
with baseline conditions, was blunted by HeartNet Implant
placement. Regional blood flow analysis revealed that the
area most affected with respect to adenosine-mediated blood
flow was the LV free wall epicardium. The reasons for the1044 The Journal of Thoracic and Cardiovascular Surreduced adenosine-mediated coronary flow reserve in the
LV free wall epicardial regions are likely multifactorial
and could be due to mechanical or neurohormonal factors.
One possible contributing factor could have been local sym-
pathetic stimulation related to the placement of the HeartNet
Implant, which may have subsequently altered G-protein
coupled responses associated with the mechanism of action
for adenosine. Additionally, an adenosine hysteresis effect
may have occurred, decreasing the coronary response to
the second adenosine infusion. Further studies using
a cross-over design would be needed to investigate this pos-
sibility. The theoretical epicardial compressive force of the
HeartNet Implant was approximately 0.5 to 2.4 mm Hg as
determined by echocardiographic data and intraoperative
HeartNet Implant measurements. This level of epicardial
pressure may have influenced coronary flow reserve given
the elevated LV end-diastolic pressures and reduced LV
wall thickness in the DCMmodel used. However, this poten-
tialmechanism remains speculative. Specifically, a recent re-
port using finite element analysismodeling suggested that an
epicardial compressive pressure of greater than 2.5 mm Hg
may negatively affect global LV systolic function (ie, cardiac
output).26 However, in the present study, which used a phys-
iologically and clinically relevant model and measurements,
there was no compromise of LV systolic performance after
acute HeartNet Implant placement. This underscores that
theoretical effects must be carefully tested in relevant
physiologic systems. Although multiple interventions, such
as adenosine infusion9 or exercise,13,14 have been
performed while measuring myocardial blood flow in this
DCM model, the direct effects of ventricular elastic
support have not previously been evaluated. Furthermore,
an important caveat is that evaluation of maximal coronary
flow reserve with adenosine infusion is more theoretical
than practical24; therefore, whether and to what extent this
blunting of coronary reserve holds clinical relevance is
unclear.
Consistent with the clinical phenotype, the porcine DCM
model causes biventricular failure.8,10-14 RV failure is of
particular clinical relevance, and owing to the geometric
and physiologic differences in this chamber, RV blood
flow was measured. Steady state RV blood flow was
unaffected by placement of the HeartNet Implant, and
blood flow increased after adenosine infusion. Thus, RV
blood flow patterns were unaffected by acute HeartNet
Implant placement. It must be recognized that maximal
coronary blood flow occurs at distinctly different points in
the cardiac cycle for the LV and RV, with the RV maximal
coronary flow during systole and the LV maximal
coronary flow during diastole. Therefore, these differential
findings with respect to the coronary reserve in the LV and
RV suggest that wall stress at end-diastole was maximized
with the HeartNet devices at maximal stretch with minimal
effects on wall stresses during systole.gery c November 2011
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DThe present study was not without limitations. First, the
HeartNet Implants were placed for the short-term, not the
long-term, as in the clinical context. Second, although the
rapid pacing–induced DCMmodel used in the present study
recapitulates a severe clinical phenotype, rapid pacing is an
unlikely cause for DCM in patients and therefore extrapola-
tion to the clinical context must be donewith caution. Third,
the present study evaluated 2 different HeartNet Implants
(models P140 and P150), by which the epicardial compres-
sive forces were estimated but not directly computed using
finite element analysis. Nevertheless, the unique findings
from the present study demonstrated that in a porcine
DCMmodel, the HeartNet Implant can be deployed without
hemodynamic compromise. Although the HeartNet Implant
did not affect myocardial blood flow under steady state con-
ditions, a region-dependent decrease in LV free wall epicar-
dial blood flow with respect to adenosine infusion was
observed with acute HeartNet Implant placement. Future
studies will need to address whether and to what degree
this effect is present with long-term placement of the Heart-
Net Implant. Furthermore, the effects of HeartNet Implant
placement on LV shape, size, and myocardial structure, as
well as load-independent indices of LV function over a lon-
ger study period, remain to be established.References
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